Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 2:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Valve Surgery Clear all
Recruiting No phase listed Observational

Detecting Changes in Arterial Blood Volume and Cardiac Efficiency

NCT07205341
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Not listed
Lead sponsor
HemoCept Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 24, 2026, 2:50 AM EDT
Recruiting Not applicable Interventional

PARTNER 3 Trial - Aortic Valve-in-Valve

NCT03003299
View directory record Official record
Conditions
Aortic Stenosis, Aortic Stenosis, Severe
Interventions
Edwards SAPIEN 3/SAPIEN 3 Ultra THV
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
Not listed
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2038
U.S. locations
50
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 43 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Jul 24, 2026, 2:50 AM EDT
Terminated Phase 2 Interventional Results available

RiaSTAP vs. Conventional Transfusion in Patients Having Heart Valve Surgery

NCT01283321
View directory record Official record
Conditions
Heart Valve Disease, Coronary Artery Disease
Interventions
Human fibrinogen concentrate, apheresis platelets
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Jul 24, 2026, 2:50 AM EDT
Recruiting Not applicable Interventional

Assessment of TRanscathetEr and Surgical Aortic BiOprosthetic Valve Thrombosis and Its TrEatment With Anticoagulation

NCT02318342
View directory record Official record
Conditions
Prosthetic Valve Thrombosis
Interventions
Warfarin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Jul 24, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing CABG and/or Cardiac Valve Surgery

NCT04564833
View directory record Official record
Conditions
AKI
Interventions
Low Dose RBT-1, High Dose RBT-1, Placebo
Drug
Lead sponsor
Renibus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
18
States / cities
Huntsville, Alabama • Los Angeles, California • Santa Barbara, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2024 · Synced Jul 24, 2026, 2:50 AM EDT
Terminated Not applicable Interventional Results available

Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement

NCT02673697
View directory record Official record
Conditions
Aortic Valve Disease, Aortic Stenosis
Interventions
Perceval valve, other stented biological valve
Device
Lead sponsor
Corcym S.r.l
Industry
Eligibility
18 Years and older
Enrollment
914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
5
States / cities
Indianapolis, Indiana • Portland, Maine • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Jul 24, 2026, 2:50 AM EDT
Active, not recruiting No phase listed Observational

A Prospective Study Comparing VivAer to Alternative Surgical Procedures to Treat Nasal Airway Obstruction in Patients With Nasal Valve Dysfunction.

NCT06922955
View directory record Official record
Conditions
Nasal Airway Obstruction
Interventions
Not listed
Lead sponsor
Aerin Medical
Industry
Eligibility
22 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jul 24, 2026, 2:50 AM EDT
Completed Not applicable Interventional Results available

Targeting Normoxia in Neonates With Cyanotic Congenital Heart Disease in the Intra-operative and Immediate Post-operative Period

NCT04452188
View directory record Official record
Conditions
Hypoplastic Left Heart Syndrome, Total Anomalous Pulmonary Venous Return, Truncus Arteriosus, Pulmonary Atresia With Ventricular Septal Defect, Transposition of the Great Arteries, Double Outlet Right Ventricle, Subpulmonary VSD, Tetralogy of Fallot, Double Outlet Right Ventricle With Subaortic Ventricular Septal Defect and Pulmonary Stenosis, Cardiopulmonary Bypass
Interventions
Normoxia (with controlled re-oxygenation), Standard of care ventilation
Other
Lead sponsor
University of Michigan
Other
Eligibility
Up to 29 Days
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Jul 24, 2026, 2:50 AM EDT
Completed Phase 4 Interventional

Prevention of Post-OP AFib Using Combination of CardiaMend and Amiodarone

NCT05681182
View directory record Official record
Conditions
Post Operative Atrial Fibrillation
Interventions
CardiaMend with the Addition of Amiodarone
Combination Product
Lead sponsor
WakeMed Health and Hospitals
Other
Eligibility
20 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Jul 24, 2026, 2:50 AM EDT
Not yet recruiting No phase listed Observational

TRIFORMIS RESILIA Real-world Study Assessing Safety and Performance (TRIBLAZE Study)

NCT07684313
View directory record Official record
Conditions
Heart Valve Diseases, Heart Diseases, Cardiovascular Diseases, Tricuspid Valve Disease
Interventions
Edwards TRIFORMIS RESILIA heart valve
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Carmel, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 24, 2026, 2:50 AM EDT
Terminated Phase 2 Interventional

A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass

NCT00271167
View directory record Official record
Conditions
Heart Diseases, Postoperative Complications
Interventions
INO-1001
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years to 90 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
5
States / cities
Boston, Massachusetts • Oklahoma City, Oklahoma • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Jul 24, 2026, 2:50 AM EDT
Completed Not applicable Interventional Results available

Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve

NCT01700439
View directory record Official record
Conditions
Aortic Valve Stenosis, Aortic Valve Stenosis With Insufficiency, Regurgitation, Aortic Valve, Aortic Valve Incompetence
Interventions
EDWARDS INTUITY valve
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
934 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
29
States / cities
Los Angeles, California • Newport Beach, California • Palo Alto, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Jul 24, 2026, 2:50 AM EDT
Completed Not applicable Interventional

An Intervention to Reduce Delirium After Cardiac Surgery

NCT02587039
View directory record Official record
Conditions
Delirium, Congenital Heart Disease, Coronary Artery Disease, Heart Valve Disease
Interventions
Remote ischemic pre-conditioning, Delirium Assessment
Procedure · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Jul 24, 2026, 2:50 AM EDT
Active, not recruiting Not applicable Interventional

Autus Valve Pivotal Study

NCT05006404
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Pulmonary Valve Replacement Surgery
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Months to 16 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2036
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 24, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Ahmed Glaucoma Valve Surgery With Mitomycin-C

NCT02805257
View directory record Official record
Conditions
Glaucoma, Primary Open Angle Glaucoma, Secondary Glaucoma, Neovascular Glaucoma
Interventions
Mitomycin-C, Balanced Salt Solution, Ahmed Glaucoma Valve Implant
Drug · Other · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 85 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 30, 2022 · Synced Jul 24, 2026, 2:50 AM EDT
Terminated Phase 2 Interventional

CTI-01 (Ethyl Pyruvate) Safety and Complication Prevention in Cardiac Surgery Patients on Cardiopulmonary Bypass (CPB)

NCT00107666
View directory record Official record
Conditions
Coronary Disease, Heart Valve Diseases
Interventions
CTI-01 (ethyl pyruvate)
Drug
Lead sponsor
Critical Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
17
States / cities
Laguna Hills, California • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2006 · Synced Jul 24, 2026, 2:50 AM EDT
Not listed No phase listed Observational

Assessment of Clinical Onset of IV Heparin in Interventional Cardiology and Cardiac Surgery

NCT04785885
View directory record Official record
Conditions
Transcatheter Aortic Valve Replacement, Cardiac Valve Annuloplasty
Interventions
iStat Handheld Blood Analyzer, Hemochron
Diagnostic Test
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Jul 24, 2026, 2:50 AM EDT
Completed Not applicable Interventional

Tricuspid Annuloplasty for Moderate Tricuspid Regurgitation Associated With Miral Operation

NCT01246947
View directory record Official record
Conditions
Cardiac Surgery, Tricuspid Valve Regurgitation
Interventions
Tricuspid valve repair, Mitral surgery alone
Procedure · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2023 · Synced Jul 24, 2026, 2:50 AM EDT
Completed Phase 2 Interventional

18-F Sodium Fluoride (18F-NaF) PET for the Assessment of Bioprosthetic Aortic Valve Durability and Outcomes

NCT03095313
View directory record Official record
Conditions
Aortic Stenosis
Interventions
18F-NaF
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Jul 24, 2026, 2:50 AM EDT
Withdrawn Phase 2 Interventional

Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery

NCT03446599
View directory record Official record
Conditions
Vasoplegia, Hypotension, Coronary Artery Disease, Cardiac Valve Disease
Interventions
Hydroxocobalamin, Methylene Blue, Normal saline
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Jul 24, 2026, 2:50 AM EDT
Active, not recruiting Not applicable Interventional Results available

Early Feasibility Study of the Neovasc Tiara™ Mitral Valve System

NCT02276547
View directory record Official record
Conditions
Mitral Valve Regurgitation
Interventions
Mitral valve replacement
Device
Lead sponsor
Shockwave Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated May 19, 2025 · Synced Jul 24, 2026, 2:50 AM EDT
Completed Not applicable Interventional Results available

Comparing the Effectiveness of a Mitral Valve Repair Procedure in Combination With Coronary Artery Bypass Grafting (CABG) Versus CABG Alone in People With Moderate Ischemic Mitral Regurgitation

NCT00806988
View directory record Official record
Conditions
Mitral Valve Insufficiency, Coronary Artery Disease
Interventions
Mitral Valve Repair, CABG
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
19
States / cities
Los Angeles, California • Atlanta, Georgia • Marietta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced Jul 24, 2026, 2:50 AM EDT
Completed Not applicable Interventional Results available

Aortic Valve Replacement With Trifecta(TM)

NCT00475709
View directory record Official record
Conditions
Aortic Valve Insufficiency, Regurgitation, Aortic Valve, Aortic Valve Incompetence, Aortic Valve Stenosis
Interventions
Trifecta Aortic Heart Valve
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,022 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
18
States / cities
Los Angeles, California • Sarasota, Florida • Maywood, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Jul 24, 2026, 2:50 AM EDT
Not listed Phase 4 Interventional

Pilot Study of Lovaza (Omega 3 Fatty Acids) to Improve Cardiac Antioxidant/Anti-inflammatory Profile Before Cardiac Surgery

NCT01046604
View directory record Official record
Conditions
Mitral Valve Regurgitation, Left Atrium Dilatation and Hypertrophy, Mitochondrial Dysfunction in the Heart, Cardiomyocyte Apoptosis, Cardiac Inflammation
Interventions
Lovaza group
Drug
Lead sponsor
East Carolina University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2013 · Synced Jul 24, 2026, 2:50 AM EDT